"Wegovy: A Game-Changer in Heart Disease Prevention, Boosting Novo Nordisk's Stock"

Novo Nordisk, the maker of the weight-loss drug Wegovy, shared data from a major trial showing that the drug lowers the risk of adverse cardiovascular events by 20%. The trial involved over 17,000 participants and measured data over a five-year period. The 2.4 mg dosage of Wegovy was found to be safe and well-tolerated. The announcement of the trial results caused Novo Nordisk's shares to surge by over 16%.